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Tumor suppressionThe transcription factor Gli1 acts in the last known step of the Hedgehog signaling, and deregulation
of Gli1 is implicated in human cancers. VHL protein is widely expressed in both fetal and adult tis-
sues and acts as a tumor suppressor. Here, we demonstrate the molecular mechanism through
which VHL inhibits the Hedgehog–Gli pathway. VHL decreased Gli1-mediated promoter transactiva-
tion as well as the expression of Hedgehog/Gli pathway target genes. Nuclear translocation of cyto-
solic Gli1 protein was inhibited by VHL via protein–protein interaction. These results indicate that
overexpression of VHL may antagonize Hedgehog–Gli activation at the post-translational level in
Hedgehog pathway-induced cancers.
Structured summary of protein interactions:
VHL-30 physically interacts with GLI1 by anti tag coimmunoprecipitation (View Interaction: 1, 2)
GLI1 and VHL colocalize by ﬂuorescence microscopy (View interaction)
VHL-19 physically interacts with GLI1 by anti tag coimmunoprecipitation (View Interaction: 1, 2)
VHL physically interacts with GLI1 by pull down (View interaction)
 2013 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
The Hedgehog signaling pathway is one of the most fundamen-
tal signal transduction pathways in embryonic development and is
highly conserved from ﬂies up through humans [1]. The pathway is
initiated by the binding of Hedgehog (Hh) ligand to PTCH1 receptor
on the target cell surface, resulting in activation of SMO and trans-
mission of the Hh signal through the protein complex [2]. Finally,
activated glioma-associated oncogene homologue (Gli), a zinc ﬁn-
ger transcription factor, translocates to nucleus whereupon it in-
creases the expression of Gli target genes such as Gli1, PTCH1,
Cyclin D1, Snail, BCL2, VEGF, and so on [3]. Gli1 and Gli2 mostly
function as transcriptional activators while Gli3 functions as a
repressor [4]. Recent ﬁndings have shown that Hh signaling is also
important in the regulation of proliferation, survival, and growth of
adult tissues [5]. Aberrant activation of the Hedgehog signaling
pathway has been implicated in several human cancers, including
medulloblastoma, rhabdomyosarcoma, basal cell carcinoma, breast
cancer, small-cell lung carcinoma, hepatocellular carcinoma, colon
cancer, pancreatic cancer, prostate cancer, and digestive tract can-
cer [6–15]. Furthermore, various studies have shown that tran-
scriptional activation of Gli1 and Gli2 is important for cellproliferation, cell cycle progression, and anti-apoptosis [14,16–
19]. Other studies have identiﬁed several negative regulators of
Gli proteins. According to recent models, Gli1 activity is mainly
regulated by nuclear-cytoplasmic shuttling [20–23].
Von Hippel–Lindau (VHL) disease is the result of inheriting a
mutation in the VHL tumor-suppressor gene [24]. VHL mutations,
including missense, non-sense, splice site, deletion, and insertion
mutations, are associated with several types of tumors, which sug-
gests that VHL protein exerts tumor suppressor activity in various
cancers [25]. The VHL gene located on chromosome locus 3p25 is
translated into two biological active proteins, pVHL30 and pVHL19.
Internal translation is initiated at the 54th codon of VHLmRNA, thus
generating pVHL19 [26]. Signs of VHL disease, including retinal
angiomas, endolymphatic sac tumors, central nervous system
hemangioblastomas, clear-cell renal cancers, and pancreatic neuro-
endocrine tumors, suggest that VHL protein has multiple functions
[27]. Speciﬁcally, VHL protein interacts with several proteins and
acts as a tumor suppressor [28]. The best characterized target of
VHLprotein is thea-subunit ofHIF-1a andHIF-2a,whicharehypox-
ia-inducible factor (HIF) family members [29]. Interaction of VHL
proteinwith the HIF-1a subunit results in ubiquitylation and degra-
dation of HIF-1a under normoxic conditions [30].
A recent study indicated that HIF-1a activates the Hedgehog
pathway under hypoxic conditions [31]. This suggests that the
tumor suppressor VHL may regulate the Hedgehog signaling
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VHL on Hedgehog/Gli pathway-related cancer development has not
yet been conﬁrmed. Therefore, we investigated whether or not VHL
can inhibit the Hedgehog pathway. We found that VHL suppressed
the Hedgehog/Gli pathway, leading to repression of Hedgehog
target gene expression. Furthermore, the protein–protein interac-
tion between VHL and Gli1 inhibited nuclear localization and
transcriptional activity of Gli1. These results suggest that VHL
may act as a tumor suppressor in some Hedgehog-related cancers.
2. Materials and methods
2.1. Plasmid constructs and reagents
The Gli1-luc reporter, PTCH1-luc reporter, and BCL2-luc repor-
ter constructs (containing the Gli1, PTCH1, and BCL2 promoters
fused to luciferase reporter, respectively) were provided by Dr.
Fritz Aberger (University of Salzburg, Salzburg, Austria). The
pcDNA3/HA-hGli1, pcDNA3/GFP-hGli1, pcDNA3/GFP-Gli1/NESmut
expression plasmids were constructed as previously describedFig. 1. VHL decreases Gli1 transcriptional activity. (A) Effect of VHL on Gli1 expressio
expression plasmids. After 12 h of transfection, the cells were treated with or without S
expression of Gli1, HA-VHL or Actin by Western blotting (top panels). Total RNAs were p
with b-actin as a loading control (bottom panels). (B) Transcriptional repression of VHL
VHL30 or VHL19, along with Gli1 promoter luciferase reporter plasmid. After 12 h of tran
were analyzed for luciferase activity. Luciferase activity was normalized for transfection
(n = 3). ⁄⁄P < 0.01 compared with mock transfectants, ##P < 0.01 compared with SAG trea
were transiently transfected with negative siRNA or siVHL. After 12 h of transfection,
analyzed for expression of Gli1, VHL or Actin by Western blotting (top panels). Total RNA
RT-PCR with b-actin as a loading control (bottom panels). (D) Transcriptional activation o
negative siRNA or siVHL, along with Gli1 promoter luciferase reporter plasmid. After 12 h
lysates were analyzed for luciferase activity. Luciferase activity was normalized for tr
means ± S.D. (n = 3). ⁄⁄P < 0.01, ⁄P < 0.05 compared with mock transfectants.[23]. VHL constructs (pcDNA3/HA-VHL19, pcDNA3/HA-VHL30,
pcDNA3/RFP-VHL30, and pcDNA3/GST-VHL30) were kindly pro-
vided by Dr. K. H. Kim. LMB (leptomycin B) and SAG was purchased
from Sigma–Aldrich. The transfection reagents jetPEI and jetPRIME
were purchased from Polyplus Transfection.
2.2. Cell culture
Huh7, HEK-293, and SKBR3 cells were maintained in DMEM
containing 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicil-
lin–streptomycin (PS) (GIBCO BRL) at 37 C in a humid atmosphere
of 5% CO2, respectively. NIH3T3 cells were cultured in DMEM con-
taining 10% fatal calf serum (FCS) and 1% (v/v) PS (GIBCO BRL) at
37 C in a humidiﬁed atmosphere containing 5% CO2.
2.3. SDS–PAGE and Western blotting
Whole cell lysates (50 lg) were subjected to SDS–PAGE (8–12%)
and transferred onto a PVDF membrane (Millipore) by semi-dry
electroblotting. Membranes were then incubated with anti-actinn. Huh7 cells were transiently transfected with empty vector, VHL30, or VHL19
AG (1 lM) dissolved in distilled water for 24 h. The cell lysates were analyzed for
repared from the cells, and then Gli1 or VHL mRNA levels were detected by RT-PCR
on Gli1 expression. Huh7 cells were transfected with expression vectors encoding
sfection, the cells were treated with or without SAG (1 lM) for 24 h. The cell lysates
efﬁciency based on corresponding b-galactosidase activity. Values are means ± S.D.
ted mock transfectants. (C) Effect of VHL-knockdown on Gli1 expression. Huh7 cells
the cells were treated with or without SAG (1 lM) for 24 h. The cell lysates were
s were prepared from the cells and then Gli1 or VHL mRNA levels were detected by
f VHL-knockdown on Gli1 expression. Huh7 cells were transiently transfected with
of transfection, the cells were treated with or without SAG (1 lM) for 24 h. The cell
ansfection efﬁciency based on corresponding b-galactosidase activity. Values are
828 H.K. Cho et al. / FEBS Letters 587 (2013) 826–832antibody (A2066; Sigma), anti-HA antibody (1 867423; Roche),
anti-Gli1 antibody (#2534; Cell Signaling), anti-patched antibody
(sc-9016; Santa Cruz Biotechnology), anti-BCL2 antibody (sc-783;
Santa Cruz Biotechnology), and anti-GFP antibody (sc-9996; Santa
Cruz Biotechnology) in TBST (Tris-buffered saline containing 1%
Tween-20) supplemented with 1% (w/v) non-fat dry milk. After
washing three times with TBST, the blotted membranes were incu-
bated with peroxidase-conjugated secondary antibody (Santa Cruz
Biotechnology) for 30 min at room temperature. After washing
three times with TBST, bands were detected using an ECL (en-
hanced chemiluminescence) system (Amersham Biosciences).
2.4. RNA isolation and RT-PCR
Total RNAs from Huh7 or NIH3T3 cells were prepared using
Trizol reagent (Invitrogen) according to the manufacturer’s recom-
mendation. Total RNAs were converted into a single-stranded
cDNA using MMLV (Moloney-murine-leukaemia virus) reverse
transcriptase (RT) (Promega) with a random hexamer at 42 C.
An aliquot (1/20 vol) of the cDNA was then subjected to PCR ampli-
ﬁcation using gene-speciﬁc primers.
2.5. Transfection and luciferase assay
Huh7 cells were seeded on a 24-well culture plate and transfec-
ted with reporter vector and b-galactosidase expression plasmid,Fig. 2. VHL suppresses the expression of Gli1 target genes. (A) Effect of VHL on of PTC
vectors encoding VHL30 or VHL19, along with PTCH1 or BCL2 promoter reporter plasmi
24 h. The cell lysates were analyzed for luciferase activity. Luciferase activity was norm
Values are means ± S.D. (n = 3). ⁄⁄P < 0.01, ⁄P < 0.05 compared with mock transfectants, ##
of VHL on PTCH1 or BCL2 expression. Huh7 cells were transiently transfected with empt
were treated with or without SAG (1 lM) for 24 h. Total RNAs were prepared from the cel
as a loading control (B). The cell lysates were analyzed for expression of PTCH1, BCL2
expression of Gli1 target genes. Huh7 cells were transiently transfected with negative si
(1 lM) for 24 h. The cell lysates were analyzed for expression of PTCH1, BCL2, VHL or A
then PTCH1, BCL2, or VHL mRNA levels were detected by RT-PCR with b-actin as a loadalong with each indicated expression plasmid or VHL siRNA (50-
GUC AUC UUC UGC AAU CGC AGU-30, knockdown efﬁciency: 70%;
Bioneer siRNA No. 1161840, knockdown efﬁciency: unchanged),
using jetPEI or jetPRIME (Polyplus Transfection), respectively. The
pcDNA3 plasmid DNA was then added to achieve the same total
amount of plasmid DNA transfection. Luciferase activity was deter-
mined using an analytical luminometer according to the manufac-
turer’s instructions. Luciferase activity was then normalized for
transfection efﬁciency based on corresponding b-galactosidase
activity. All assays were performed at least in triplicate.
2.6. Co-immunoprecipitation and in vivo GST (gluthathione
transferase) pull-down assay
Cells were lysed in radio-immunoprecipitation assay buffer. Cell
lysates were mixed with anti-HA antibody (1 867423; Roche) or
anti-GFP antibody (sc-9996; Santa Cruz Biotechnology) at 4 C for
12 h with gentle agitation. Immune complexes were then collected
on protein G-Sepharose beads (Invitrogen) and incubated for 2 h in
a cold-room. After washing three times extensively with RIPA buf-
fer, the precipitates were boiled with an equal volume of 2 Lae-
mmli sample buffer, separated by SDS–PAGE, and subjected to
Western blot analysis.
For GST pull-down assay, whole cell lysates were obtained by
subsequent centrifugation at 13000g for 20 min at 4 C. Cell ly-
sates were subjected to SDS–PAGE (6–12% gels) and transferredH1 or BCL2 transcriptional activities. Huh7 cells were transfected with expression
d. After 12 h of transfection, the cells were treated with or without SAG (1 lM) for
alized for transfection efﬁciency based on corresponding b-galactosidase activity.
P < 0.01, ##P < 0.05 compared with SAG treated mock transfectants. (B and C) Effect
y vector, VHL30, or VHL19 expression plasmids. After 12 h of transfection, the cells
ls, and then PTCH1, BCL2, or VHL mRNA levels were detected by RT-PCR with b-actin
, HA-VHL, or Actin by Western blotting (C). (D) Effect of VHL-knockdown on the
RNA or siVHL. After 12 h of transfection, the cells were treated with or without SAG
ctin by Western blotting (top panels). Total RNAs were prepared from the cells and
ing control (bottom panels).
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Membranes were then incubated with anti-GST antibody (sc-
138; Santa Cruz Biotechnology) or anti-GFP antibody (sc-9996;
Santa Cruz Biotechnology) in TBST (Tris-buffered saline containing
1% Tween-20) supplemented with 3% (w/v) non-fat dry milk. The
bands were detected using an ECL (enhanced chemiluminescence)
system (Amersham Biosciences).
2.7. Fluorescence microscopy in living cells
Following transfection, cells were incubated for 24 h. Prior to
imaging, cells were counterstained with Hoechst dye for 10 min
at 37 C in order to stain nuclei. Cells were visualized with a Zeiss
Axiovert 200 M microscope.
2.8. Statistical analysis
Statistical analyses were carried out by unpaired or paired t test
as appropriate. All data are reported as the means ± S.D. P value of
<0.05 was considered as signiﬁcant.
3. Results
3.1. VHL decreases the expression of Gli1 gene
To determine whether or not VHL regulates the expression of
Hedgehog pathway-related target genes, the expression of Gli1
protein was investigated in Huh7 cells following transient trans-
fection with VHL30 or VHL19 expression vector. The expression
of Gli1 protein and mRNA was down-regulated by VHL30 or
VHL19, and SAG (SMO agonist/Hedgehog signaling activator)-in-
duced Gli expression was attenuated by VHL30 or VHL19
(Fig. 1A) [32]. To conﬁrm whether or not the effect of VHL on
Gli1 expression is dependent on the Gli1 promoter, luciferase assay
was performed with Gli1 promoter linked to the luciferase gene. AsFig. 3. VHL interacts with Gli1. (A) Interaction between GFP-Gli1 and HA-VHL by co-imm
HA-VHL19, or HA vector, along with GFP-Gli1 plasmid (left), or with GFP-Gli1 or GFP vect
were subjected to immunoprecipitation (IP) with anti-HA (left) antibody or anti-GFP (rig
antibody (right). (B) Interaction between GFP-Gli1 and HA-VHL by in vivo GST pull-down
protein, along with GFP-Gli1 expression vector. After 24 h of transfection, cell lysates wer
blotting using the indicated antibodies.shown in Fig. 1B, VHL30 or VHL19 signiﬁcantly suppressed Gli1
and SAG-induced Gli1 promoter activity. Small interfering RNA
(siRNA) is involved in the RNA interference (RNAi) pathway, where
it interferes with the expression of a speciﬁc gene. To conﬁrm the
effect of VHL on expression of Gli1, we used siRNA against VHL. As
shown in Fig. 1C and D, Gli1 expression and promoter activity were
increased by knock-down of the VHL gene. Further, SAG-induced
Gli expression and promoter activity were enhanced by knock-
down of the VHL gene. These results indicate that VHL proteins in-
hibit Gli1 expression at the transcriptional level.
3.2. VHL represses the expression of Hedgehog target genes
To investigatewhetherVHL30andVHL19affect the expressionof
Hedgehog/Gli target genes, a luciferase reporter assay was per-
formed. PTCH1 and BCL2 have been well characterized as markers
of Hedgehog signaling activation [33]. As shown in Fig. 2A, both
VHL30 and VHL19 decreased PTCH1 and BCL2 promoter activities
under control and Hedgehog signaling activated conditions. To fur-
ther investigate changes in the mRNA and protein levels of Hedge-
hog/Gli1 target genes in the presence of VHL, RT-PCR and Western
blot analyses were performed. VHL also inhibited the expression of
PTCH1 and BCL2 at the mRNA and protein levels under control and
Hedgehog signaling activated conditions (Fig. 2B and C). These re-
sults suggest that VHL suppresses the Hedgehog signaling pathway
via repression of Gli1-mediated target genes. Further, protein and
mRNA expression of Hedgehog/Gli target genes were increased by
knock-down of the VHL gene (Fig. 2D). These results provide strong
evidence that VHL decreases the expression of Hedgehog/Gli target
genes through inactivation of the Hedgehog/Gli signaling pathway.
3.3. VHL interacts with Gli1 protein
To determine the molecular mechanism through which VHL
represses Gli1 transcriptional activity, a co-immunoprecipitationunoprecipitation assay. HEK293 cells were transiently transfected with HA-VHL30,
or, along with HA-VHL30 or HA-VHL19 (right). After 24 h of transfection, cell lysates
ht) antibody, followed by Western blotting using anti-GFP antibody (left) or anti-HA
assay. HEK293 cells were transfected with vector expression GST alone or GST-VHL
e obtained and immobilized onto glutathione-Sepharose beads, followed byWestern
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tated with HA-VHL30 or HA-VHL19, but not with the control pro-
tein HA, as shown by anti-GFP Western blotting (Fig. 3A, left
panel). Inversely, HEK293 cells were co-transfected with GFP-
Gli1 or GFP along with HA-VHLs, followed by gel-fractionation
and Western blotting analysis. VHL30 and VHL19 were co-immu-
noprecipitated with GFP-Gli1 protein only (Fig. 3A, right panel).
In addition, to conﬁrm a physical interaction between VHL and
Gli1 protein, in vivo GST pull-down assay was performed. The
GST-VHL-bound GFP-Gli1 protein was detected via immunoblot-
ting using anti-GFP antibody. As shown in Fig. 3B, GFP-Gli1 bound
to GST-VHL, but not to GST protein. The results of the co-immuno-
precipitation and in vivo GST pull-down assays imply that VHL
speciﬁcally interacts with Gli1 protein.
3.4. VHL co-localizes with Gli1 in the cytoplasm and disturbs Gli1
nuclear localization
Since Gli1 is a nuclear-cytoplasmic shuttling protein [34], Gli1
proteins can be found in the cytoplasm as well as the nucleus
depending on the context [4,22]. To investigate whether or not
VHL co-localizes with Gli1 protein, SKBR3 cells were co-transfected
with GFP-Gli1 and RFP-VHL expression vectors, after which subcel-
lular localization was examined by ﬂuorescence microscopy in liv-
ing cells. The subcellular localization pattern of Gli1 is deﬁned as N,Fig. 4. VHL co-localizes with Gli1 in the cytoplasm and disturbs Gli1 nuclear localiza
transfected with RFP or RFP-VHL vectors, along with GFP-Gli1 expression vector and
ﬂuorescence microscopy of living cells. Histogram of the quantifying changes in Gli1 su
Effect of LMB on VHL-mediated Gli1 subcellular localization. After 24 h of transfection, ce
to label nuclei, and cell imaging was assessed by ﬂuorescence microscopy of living cells
Gli1-NESmut expression vectors were co-transfected along with RFP or RFP-VHL express
label nuclei, and cell imaging was assessed by ﬂuorescence microscopy. (D) Histogram
(left) and Gli1-NESmut (right) after RFP-VHL co-expression.nucleus; C, cytoplasm; and N/C, nucleus and cytoplasm. As shown
in Fig. 4A, GFP-Gli1 co-localized with RFP-VHL in the cytoplasm,
but not with RFP protein. These results indicate that VHL physically
interacts with Gli1 protein, suggesting that VHL may play an
important role as a negative regulator of Gli1 nuclear localization.
Previous studies have reported that although VHL is predomi-
nantly cytoplasmic, it can shuttle between the cytoplasm and nu-
cleus [35]. The biological function of VHL nuclear-cytoplasmic
shuttling could be important for its anti-tumor effects, since the
same exon (exon 2) that controls shuttling is also a b-domain-bind-
ing surface for VHL-E3 ligase [36]. To more directly conﬁrm the
role of VHL in the Gli1–VHL interaction, a nuclear export inhibitor
was used. It is known that Gli1 protein activity can be suppressed
by altering its subcellular localization from the nucleus to the cyto-
plasm, and nuclear export of Gli1 protein is chromosome region
maintenance homologue 1 (CRM1)-dependent [34]. Leptomycin B
(LMB), a CRM1-dependent export inhibitor, induced an increase
in the nuclear localization of Gli1. On the other hand, co-transfec-
tion of RFP-VHL but not RFP disturbed this LMB-dependent nuclear
accumulation of GFP-Gli1 protein (Fig. 4B). To conﬁrm these re-
sults, Gli1-NESmut, in which two amino acids (Leu501 and Leu503)
in the nuclear export sequence (NES) are replaced with alanine res-
idues, was used. As shown in Fig. 4C, VHL inhibited the nuclear
localization of Gli1-NESmut protein. The nuclear localization pat-
tern of Gli1 was reduced by about 40% upon VHL co-transfectiontion. (A) Co-localization of Gli1 and VHL in the cytoplasm. SKBR3 cells were co-
were counterstained with Hoechst to label nuclei. Cell imaging was assessed by
bcellular localization after RFP-VHL co-expression is shown in the right panel. (B)
lls were treated with 5 nM LMB for 8 h. The cells were counterstained with Hoechst
. (C) Effect of Gli1-NES mutant on VHL-mediated Gli1 subcellular localization. GFP-
ion vector. After 24 h of transfection, the cells were counterstained with Hoechst to
of the quantifying changes in GFP-Gli1 subcellular localization in LMB-treated cells
H.K. Cho et al. / FEBS Letters 587 (2013) 826–832 831(Fig. 4D). These results demonstrate that VHL may function as a
negative regulator of the Hedgehog/Gli pathway.
4. Discussion
This study focuses on the function of VHL in Hedgehog signaling
pathway. Herein, VHL30 and VHL19 showed a similar ability to
down-regulate the expression of Hedgehog target genes. Hergovich
et al. showed that VHL30 localizes to both nuclear and cytoplasmic
compartments, whereas VHL19 predominantly localizes to the nu-
cleus [35]. Despite a difference in localization, the VHLs have a sim-
ilar ability to down-regulate the expression of Hedgehog target
genes, implying that they may have other mechanisms that inhibit
the Hedgehog signaling. For example, VHL30 or VHL19 mainly
interact with cytoplasmic or nuclear Gli1, and thereby may inhibit
Gli1 transcriptional activity.
It is well known that VHL interacts with and targets HIF-1a for
ubiquitin-mediated proteolysis under normal oxygen conditions
[36]. This VHL-mediated proteolytic degradation of HIF suppresses
a transcription program that is associated with the cellular adap-
tive response to hypoxia [37]. However, under hypoxic conditions,
the ubiquitin ligase activity of VHL and the interaction between
VHL and HIF-1a are inhibited [28]. Stabilized HIF-1a promotes
the expression of a large panel of target genes involved in growth,
motility, metabolism, and angiogenesis, including vascular endo-
thelium growth factor (VEGF), parathyroid hormone-related pro-
tein (PTHrP), tumor growth factors (TGFs), and glucose
transporters [30]. Recently, it has become clear that the Hedgehog
pathway is activated in ischaemic adult tissues, including astro-
cytes, cardiomyoblast cells, neural progenitor cells, and human
pulmonary arterial smooth muscle cells (HPASMCs), in response
to hypoxia [38]. A recent investigation by Bijlsma et al. showed
that HIF-1a accumulation lead to the activated Hedgehog response
[31]. Further, an increase of HIF-1a due to hypoxic conditions can
lead to the de novo expression of Shh and PTCH1, followed by
Hedgehog pathway activation [31].
The present data show that VHL directly binds to Gli1 protein
and suggest two molecular models for Gli1 inhibition by VHL.
One is a direct model in which VHL directly binds to Gli1 protein
and suppresses Gli1 nuclear localization. The other is an indirect
model wherein HIF-1a acts as a mediator of Gli1 inhibition by
VHL. Under normal conditions, the VHL-E3 ubiquitin protein ligase
complex degrades HIF-1a [28]. Under hypoxic conditions, the
ubiquitin ligase activity of VHL is inhibited, resulting in sequential
activation of HIF-1a and up-regulation of Gli1 transcription, lead-
ing to tumor progression. However, we think that inhibition of
Gli1 transcriptional activity by VHL is unlikely to occur through
ubiquitin ligase activity of VHL. Therefore, we suppose that if
VHL is over-expressed in hypoxic conditions, it will attenuate
HIF-1a-induced Hedgehog response. Further, we suppose that mu-
tated VHL with impaired ubiquitin ligase activity can attenuate the
Hedgehog signaling, leading to down-regulation of Gli1, PTCH1,
and Bcl2 expression. These suggestion needs to be conﬁrmed in
further experiments.
So farmore than400mutations inVHLhavebeen identiﬁed, com-
prising for more than 150 independent intragenic mutation events.
The study about correlation between VHLmutations and Hedgehog
signaling activation has not yet been performed; however, we sup-
pose that there is Hedgehog signaling activation-related cancer
among the VHL mutations. Because pancreatic cancer is related to
both VHL andHedgehog signaling, the study about relation between
VHL mutation and Hedgehog signaling need to be performed in pa-
tients with pancreatic cancer as the priority.
In summary, the present study determined if and how VHL sup-
presses the Hedgehog/Gli signaling pathway. These data indicatethat VHL inhibits the expression of Gli1 target genes as well as nu-
clear localization of Gli1 via protein–protein interactions. These re-
sults might provide evidence for VHL as a tumor suppressor in
Hedgehog pathway-related cancers, especially pancreatic cancer.
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